跳到正文
原文
Medical Xpress·· 23 天前精选AI 评分74

pazopanib与bevacizumab交替方案在晚期透明细胞肾癌I/II期试验中延长无进展与总生存

Combining targeted therapies significantly boosted survival in kidney cancer study

AI 导读

pazopanib与bevacizumab交替方案在未经治疗的晚期透明细胞肾癌I/II期单臂试验中,51例患者中位无进展生存24.8个月、中位总生存63.2个月。中位随访63.7个月,按IMDC标准归为favorable-risk的33例患者PFS为28.5个月、OS为76.9个月。常见严重不良反应为高血压和肝酶升高,结果发表于The Lancet Oncology。

推荐理由

单臂I/II期试验给出中位无进展生存24.8个月与总生存63.2个月,可与一线TKI单药的历史数据对照阅读。

正文 · 原文
Combining 2 VEGF-blocking targeted therapies significantly boosted survival in kidney cancer study
Survival endpoints in phase 2. Credit: The Lancet Oncology (2026). DOI: 10.1016/s1470-2045(26)00394-3

Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer. Saby George, M.D., FACP, professor of oncology in the Department of Medicine, is principal investigator of the trial and first author of the study, newly published in The Lancet Oncology.

The strongest benefit was seen in favorable-risk patients, who made up the majority of the 51 patients enrolled in the nationwide clinical trial, NCT01684397, conducted at five academic cancer centers.

"This novel regimen of pazopanib alternating with bevacizumab was found to be safe and efficacious in untreated patients with advanced clear cell kidney cancer," says George. "The regimen was also reasonably well tolerated by patients and delayed development of treatment resistance leading to prolonged progression-free survival."

When pazopanib, a tyrosine kinase inhibitor (TKI), is given alone as the first-line treatment for patients with previously untreated metastatic clear cell renal cell carcinoma (mccRCC), median progression-free survival is just 9.2 months, and overall survival ranges from 28.4 to 29.3 months. After treatment with both bevacizumab and pazopanib, 51 patients in the phase 2 portion of the clinical trial had a median progression-free survival (PFS) of 24.8 months and median overall survival (OS) of 63.2 months after a median follow-up of 63.7 months.

But 33 of the 51 patients—categorized as at "favorable risk" according to the guidelines of the International Metastatic RCC Database Consortium (IMDC)—fared even better, with a PFS of 28.5 months and OS of 76.9 months. This improvement is noteworthy because while patients with advanced renal cell carcinoma are typically treated with immunotherapy/TKI combination therapies, which can improve both progression-free and overall survival, these combinations fail to show significant improvement in overall survival in favorable-risk patients.

"The benefit from this novel regimen of pazopanib and bevacizumab was comparable to or better than that of the contemporary immunotherapy combinations in the favorable-risk patients," notes George. "This is significant due to the lower cost of this regimen compared to the immunotherapy combinations."

The researchers believe this is the first clinical trial in kidney cancer to demonstrate both safety and efficacy using a combination of two drugs that both block vascular endothelial growth factor (VEGF), a protein that promotes the growth of new blood vessels that can "feed" the tumor with oxygen and nutrients. When multitargeted TKIs like pazopanib are used alone, drug resistance increases with every treatment cycle, due partly to rising VEGF ligand levels. But bevacizumab, a targeted monoclonal antibody, binds to VEGF and removes it from circulation.

Phase 1 of the two-part clinical trial determined the optimal doses for both drugs—800 mg of pazopanib daily on days 1–28, plus 10 mg/kg of bevacizumab on days 36 and 50 of a 10-week cycle. Phase 2 enrolled 51 treatment-naive patients who received the recommended phase 2 dose established in the phase 1 portion.

High blood pressure and elevated liver enzymes were the most common serious side effects.

George and his colleagues note that this novel combination may also benefit patients who are unable to receive immunotherapy agents, patients whose disease progresses with adjuvant pembrolizumab and patients in resource-limited countries.

Rahul Parikh, M.D., Ph.D., of the University of Kansas is senior author of the study. The investigator-initiated clinical trial enrolled patients at Roswell Park, the University of Kansas Cancer Center, Karmanos Cancer Center in Michigan, the University of Pittsburgh Cancer Center and the Medical College of Wisconsin. The research team represented those institutions as well as the Jacobs School of Medicine at the University at Buffalo.

Publication details

Saby George et al., Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial, The Lancet Oncology (2026). DOI: 10.1016/s1470-2045(26)00394-3

Journal information: Lancet Oncology

Clinical categories

OncologyUrology

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Combining targeted therapies significantly boosted survival in kidney cancer study (2026, October 28) retrieved 28 October 2026 from https://medicalxpress.com/news/2026-10-combining-therapies-significantly-boosted-survival.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com